ClinicalTrials.Veeva

Menu

Evaluation of the Value of Cerebral Perfusion Scintigraphy in the Study of Post-stroke Fatigability

U

University Hospital, Strasbourg, France

Status

Unknown

Conditions

Fatigability Post Stroke

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

At present there is no consensus for post-stroke imaging except for the realization of early cerebral CT at 24 hours post-thrombolysis. The use of cerebral perfusion scintigraphy would predict the course of a stroke. Indeed, it has been shown that a good perfusion is linked to a good evolution of the neurological deficit. This test is used routinely to evaluate cerebral perfusion in patients with stroke. This technique was also used to study the mechanisms of post-stroke aphasia and to highlight neuronal disconnections after stroke, a reflection of the functioning of neural networks.

Neuropsychological tests are almost always done at 3 months. Fatigue is studied: PSF scale at 3 months, 6 months and 2 years. Research needs to be continued in this area because the pathophysiology remains unknown and the symptoms are disabling for patients. Using cerebral perfusion imaging would bring elements of understanding of this mechanism and ultimately improve the management of patients.

Enrollment

32 estimated patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients: 18 to 60 years old at the initial diagnosis
  • Admission for transient ischemic attack, stroke, dissection, TVC
  • RANKIN less than or equal to 2
  • Neuropsychological tests at +3 months: MoCA> 26 (to eliminate cognitive deteriorations too important for the good realization of the battery)
  • Absence of psychiatric history
  • Absence of psychotropic medication
  • No history of stroke
  • No complaint of pre-stroke fatigue
  • Having signed the consent form

Exclusion criteria

  • Impossibility of giving the subject or his family enlightened information (subject in emergency situation, difficulties in understanding the subject, etc.)
  • Subject under the protection of justice
  • Subject under guardianship or curatorship
  • Refusal of the patient to participate in the study

Trial contacts and locations

1

Loading...

Central trial contact

Izzie Jacques NAMER, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems